trending Market Intelligence /marketintelligence/en/news-insights/trending/EI9wGAeMyZC0QAey1boM5Q2 content esgSubNav
In This List

Teva seeks US FDA approval for migraine treatment

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Teva seeks US FDA approval for migraine treatment

Teva Pharmaceutical Industries Ltd. filed a biologics license application, seeking approval for its migraine treatment fremanezumab from the U.S. Food and Drug Administration.

The submission is supported by the results of two phase 3 trials that involved patients with episodic and chronic migraine. The drug met its primary and secondary endpoints reducing the number of migraine days.

Fremanezumab is a fully humanized monoclonal antibody targeting the calcitonin gene-related peptide ligand, a well-validated target in migraine.